Prostate Cancer Trial, Recruiting NCT07370597 Sponsor: Jules Bordet Institute Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07370597
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are male, aged 18 or older, and have been diagnosed with prostate cancer (a specific type called adenocarcinoma).
  • People whose prostate cancer has spread to other parts of the body and is getting worse, shown by two rising PSA blood test results in a row, or by changes seen on a bone scan or other imaging.
  • People whose cancer shows a significant level of a protein marker called PSMA on a special scan, meaning at least one affected area lights up more brightly than the liver on that scan.
  • People who are able to begin treatment within four weeks of having their PSMA PET/CT scan (a type of full-body imaging test).
  • People who are willing and able to follow all of the study's requirements throughout the trial.

Who may not be able to join:

  • No exclusion criteria were listed in the provided information (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 02.54137.81

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Jules Bordet Institute
Registry
ClinicalTrials.gov
Start date
1 February 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Patient-based response defined as a decline of serum PSA ≥50% at 12th weeks (after 2 cycles) after treatment initiation.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov